Free Allergy and Immunology CME 2017‑2018 | CMEList.com

 


Scientia CME Immunology - Allergy CME Free Dermatology CME
Posted by...Bernard Sklar, MD.
CME Credit Hours....1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...ALLERGY, DERMATOLOGY.
CME Credit Expires...Two years after release.
Financial Support...Various commercial supporters.
Scientia CME Immunology - Allergy CME has one selection:
Hereditary Angioedema (HAE): Therapeutic Updates, Best Practices, and Barriers to Care (1 hr CME)
Asthma and allergic asthma: personalizing treatment to the patient and therapeutic updates (1 hr CME)
 In order to get credit from ScientiaCME, you must first establish a username and password.

Psoriasis: A Targeted Approach to the Patient with Moderate-to-Severe Plaque Psoriasis Free Psoriasis CME
Live online November 16, 2016, and available on demand through May 16, 2017.
Posted by...Bernard Sklar, MD.
Free Obesity CME Credit hours...1.0. 
CME Credits Awarded by....University of Cincinnati.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for dermatologists, rheumatologists, internists, primary care physicians, family physicians, nurse practitioners, physician assistants, and health care professionals involved in the management of patients with psoriasis.
Educational material updated....November 16, 2016.
Expiration of CME credit...May 16, 2017.
Financial Support...Novartis Pharmaceutical Corporation and Lilly.
After viewing Psoriasis: A Targeted Approach to the Patient with Moderate-to-Severe Plaque Psoriasis, you will be better able to:
• Evaluate the impact of moderate-to-severe psoriasis on patients' quality of life and the importance of effective therapy to improve patients' lives
• Compare and contrast the evidence for efficacy and safety of biologics and other targeted systemic therapies for moderate-to-severe plaque psoriasis
• Integrate evidence-based treatment algorithms for moderate-to-severe plaque psoriasis for the effective use of newer biologics and targeted systemic therapies

Crohn's: Meeting the Challenge of Managing Crohn's Disease Across the Spectrum Free Crohn's Disease CME
Live online November 3, 2016, and available on demand through May 3, 2017.
Posted by...Bernard Sklar, MD.
Free Immunology CME Credit hours...1.0. 
CME Credits Awarded by....University of Cincinnati.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for gastroenterologists and other health care professionals involved in the management of patients with psoriasis.
Educational material updated....November 3, 2016.
Expiration of CME credit...May 3, 2017.
Financial Support...Not Stated.
After viewing Meeting the Challenge of Managing Crohn's Disease Across the Spectrum  you will be better able to:
• Outline the recommended treatment algorithm for mild-to-severe active Crohn's disease
• Describe the efficacy and risks associated with available therapies for moderate-to-severe active Crohn's disease
• Identify new treatments on the horizon and their potential place in therapy of Crohn's disease

RA Emerging DMARDS: Treat-to-Target Strategies in Rheumatoid Arthritis: Leveraging Novel and Emerging DMARDS to Achieve Goals Free Rheumatology CME
Live online December 1, 2016, and available on demand through April 1, 2017.
Posted by...Bernard Sklar, MD.
Free Rheumatology CME Credit hours...1.0. 
CME Credits Awarded by....Albert Einstein College of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for rheumatologists, primary care physicians, family physicians, nurse practitioners, physician assistants.
Educational material updated....December 1, 2016.
Expiration of CME credit...April 1, 2017.
Financial Support...Eli Lilly and Company.
After viewing Treat-to-Target Strategies in Rheumatoid Arthritis,  you will be better able to:
• Use recommended RA assessment tools to inform decisions about drug therapy
• Evaluate the evidence for novel and emerging biologics and small-molecule DMARDs and their place in RA therapy
• Consider modifying therapy in patients who are in remission or have low disease activity (LDA)